Cargando…
Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer
The aim of this study is to evaluate the factors affecting the objective response rate (ORR) after neoadjuvant therapy of taxol plus platinum (TP) regimen combined with programmed cell death protein-1 (PD-1) inhibitors for esophageal cancer, and establish a predictive model for forecasting ORR. Acco...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102326/ https://www.ncbi.nlm.nih.gov/pubmed/37055490 http://dx.doi.org/10.1038/s41598-023-33038-w |
_version_ | 1785025670500319232 |
---|---|
author | Ma, Rulan Yuan, Dawei Mo, Caijing Zhu, Kun Dang, Chengxue Zhang, Yong Yin, Jianhao Li, Kang |
author_facet | Ma, Rulan Yuan, Dawei Mo, Caijing Zhu, Kun Dang, Chengxue Zhang, Yong Yin, Jianhao Li, Kang |
author_sort | Ma, Rulan |
collection | PubMed |
description | The aim of this study is to evaluate the factors affecting the objective response rate (ORR) after neoadjuvant therapy of taxol plus platinum (TP) regimen combined with programmed cell death protein-1 (PD-1) inhibitors for esophageal cancer, and establish a predictive model for forecasting ORR. According to the inclusion and exclusion criteria, consecutive esophageal cancer patients who were treated in the First Affiliated Hospital of Xi’an Jiaotong University from January 2020 to February 2022 were enrolled in this study as a training cohort, while patients who were treated in the Shaanxi Provincial Cancer Hospital Affiliated to Medical College of Xi’an Jiaotong University from January 2020 to December 2021 were enrolled as a validation cohort. All patients were treated with resectable locally advanced esophageal cancer and received neoadjuvant chemotherapy combined with immunotherapy. The ORR was defined as the sum of complete pathological response, major pathological response and partial pathological response. Logistic regression analysis was performed to determine the factors that might be related to the ORR of the patients after neoadjuvant therapy. The nomogram based on the result of regression analysis was established and verified to predict the ORR. In this study, 42 patients were included as training cohort and 53 patients were included as validation cohort. Chi-square analysis showed that neutrophil, platelet, platelet-to-lymphocytes ratio (PLR), systemic immune-inflammation index (SII), D-dimer and carcinoembryonic antigen (CEA) between ORR group and non-ORR group were significantly different. Logistic regression analysis showed that aspartate aminotransferase (AST), D-dimer and CEA were independent predictors of ORR after neoadjuvant immunotherapy. Finally, a nomogram was established based on AST, D-dimer and CEA. Internal validation and external validation revealed that the nomogram had a good ability to predict ORR after neoadjuvant immunotherapy. In conclusion, AST, D-dimer and CEA were the independent predictors of ORR after neoadjuvant immunotherapy. The nomogram based on these three indicators showed a good predictive ability. |
format | Online Article Text |
id | pubmed-10102326 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-101023262023-04-15 Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer Ma, Rulan Yuan, Dawei Mo, Caijing Zhu, Kun Dang, Chengxue Zhang, Yong Yin, Jianhao Li, Kang Sci Rep Article The aim of this study is to evaluate the factors affecting the objective response rate (ORR) after neoadjuvant therapy of taxol plus platinum (TP) regimen combined with programmed cell death protein-1 (PD-1) inhibitors for esophageal cancer, and establish a predictive model for forecasting ORR. According to the inclusion and exclusion criteria, consecutive esophageal cancer patients who were treated in the First Affiliated Hospital of Xi’an Jiaotong University from January 2020 to February 2022 were enrolled in this study as a training cohort, while patients who were treated in the Shaanxi Provincial Cancer Hospital Affiliated to Medical College of Xi’an Jiaotong University from January 2020 to December 2021 were enrolled as a validation cohort. All patients were treated with resectable locally advanced esophageal cancer and received neoadjuvant chemotherapy combined with immunotherapy. The ORR was defined as the sum of complete pathological response, major pathological response and partial pathological response. Logistic regression analysis was performed to determine the factors that might be related to the ORR of the patients after neoadjuvant therapy. The nomogram based on the result of regression analysis was established and verified to predict the ORR. In this study, 42 patients were included as training cohort and 53 patients were included as validation cohort. Chi-square analysis showed that neutrophil, platelet, platelet-to-lymphocytes ratio (PLR), systemic immune-inflammation index (SII), D-dimer and carcinoembryonic antigen (CEA) between ORR group and non-ORR group were significantly different. Logistic regression analysis showed that aspartate aminotransferase (AST), D-dimer and CEA were independent predictors of ORR after neoadjuvant immunotherapy. Finally, a nomogram was established based on AST, D-dimer and CEA. Internal validation and external validation revealed that the nomogram had a good ability to predict ORR after neoadjuvant immunotherapy. In conclusion, AST, D-dimer and CEA were the independent predictors of ORR after neoadjuvant immunotherapy. The nomogram based on these three indicators showed a good predictive ability. Nature Publishing Group UK 2023-04-13 /pmc/articles/PMC10102326/ /pubmed/37055490 http://dx.doi.org/10.1038/s41598-023-33038-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ma, Rulan Yuan, Dawei Mo, Caijing Zhu, Kun Dang, Chengxue Zhang, Yong Yin, Jianhao Li, Kang Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer |
title | Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer |
title_full | Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer |
title_fullStr | Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer |
title_full_unstemmed | Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer |
title_short | Factors affecting the ORR after neoadjuvant therapy of TP regimen combined with PD-1 inhibitors for esophageal cancer |
title_sort | factors affecting the orr after neoadjuvant therapy of tp regimen combined with pd-1 inhibitors for esophageal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102326/ https://www.ncbi.nlm.nih.gov/pubmed/37055490 http://dx.doi.org/10.1038/s41598-023-33038-w |
work_keys_str_mv | AT marulan factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer AT yuandawei factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer AT mocaijing factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer AT zhukun factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer AT dangchengxue factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer AT zhangyong factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer AT yinjianhao factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer AT likang factorsaffectingtheorrafterneoadjuvanttherapyoftpregimencombinedwithpd1inhibitorsforesophagealcancer |